Pemetrexed News and Research

RSS
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Nivolumab drug improves survival for non-SQ NSCLC patients

Nivolumab drug improves survival for non-SQ NSCLC patients

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

UK Court passes verdict in favor of Lilly relating to Alimta vitamin regimen patent claim

UK Court passes verdict in favor of Lilly relating to Alimta vitamin regimen patent claim

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

SRS fails to improve survival for NSCLC brain metastases patients

SRS fails to improve survival for NSCLC brain metastases patients

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed plus erlotinib shows benefits in NSCLC